Saline at lower tonicity in CF (SALTI-CF) trial comparing 0.9% v 3% v 6% nebulised saline.

Tiffany J DwyerMark R ElkinsRuth DenticeSamantha ForbesPeter CooperAdam JaffeJennifer BishopPeter Gordon Middleton Peter A B WarkPeter T P Byenull null

Published in: The European respiratory journal (2023)

Dilution of 6% saline to 3% maintains the benefits for lung function and exacerbation prevention however the positive impacts of 6% saline on quality of life and time to intravenous antibiotics for pulmonary exacerbations are lost.

Keyphrases

cystic fibrosis
lung function
chronic obstructive pulmonary disease
air pollution
clinical trial
study protocol
high dose
open label
liquid chromatography tandem mass spectrometry
phase ii
high resolution
simultaneous determination
intensive care unit
placebo controlled